Quoin Pharmaceuticals Announces Distribution and Licensing Agreement with Foremost Rare Disease Company for Greater China

On June 16, 2022,- Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company fixated on orphan and rare diseases, announced that it has attained a distribution agreement and license with Hong Kong WinHealth Pharma Group Ltd. for its principal product candidate, QRX003 for Netherton Syndrome along with a second pipeline product, QRX004 for Epidermolysis Bullosa.

The agreement will empower Quoin to deliver healthcare professionals and patients in greater China, including Macau, Taiwan, and Hong Kong, with access to its products upon receiving regulatory approval. With this newest agreement, distribution partnerships and licenses have now been recognized for QRX003 in approximately 60 countries globally.

According to Dr. Michael Myers, the CEO of Quoin, they are pleased to announce what they believe could eventually become a revolutionary partnership for Quoin. WinHealth has widespread experience in effectively bringing ground-breaking rare disease products to the market in South East Asia and China, in general. Their portfolio of global associations is evidence of their dedication to serving the rare disease community and Quoin is eager to become the latest addition to this astral list.

Netherton Syndrome is a distressing rare disease that brutally impacts patients and their life quality while placing enormous stress on their caregivers and families. Quoin’s all-encompassing mission is to confirm that every patient, everywhere, can get access to their products once approved. This latest agreement brings Quoin another step closer to achieving its goal.